HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the... |

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
metoprolol tartrate injection, USP - VIAL
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
metoprolol tartrate injection, USP - VIAL Quick Finder
1 INDICATIONS AND USAGE
Metoprolol tartrate Injection is indicated in the treatment of definite or suspected acute myocardial infarction in hemodynamically stable patients to reduce cardiovascular mortality when used in...
2 DOSAGE AND ADMINISTRATION
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Initiate treatment in a...
3 DOSAGE FORMS AND STRENGTHS
Injection: 5 mg metoprolol tartrate supplied in 5 mL Single-dose glass Fliptop Vial.
4 CONTRAINDICATIONS
Hypersensitivity to Metoprolol tartrate and related derivatives, or to any of the excipients; hypersensitivity to other beta-blockers (cross sensitivity between beta-blockers can occur).
Metoprolol...
5 WARNINGS AND PRECAUTIONS
5.1 Bradycardia
Bradycardia, including sinus pause, heart block, and cardiac arrest have occurred with the use of Metoprolol tartrate....
6 ADVERSE REACTIONS
The following adverse reactions are described elsewhere in labeling:
- Worsening angina or myocardial infarction [see Warnings and Precautions (5...
7 DRUG INTERACTIONS
7.1 Catecholamine Depleting Drugs and Monoamine Oxidate (MAO) Inhibitors
Catecholamine depleting drugs (e.g., reserpine) and monoamine oxidase (...
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
Available data from...
10 OVERDOSAGE
Signs and Symptoms - Overdosage of metoprolol may lead to severe bradycardia, hypotension, and cardiogenic shock. Clinical...
11 DESCRIPTION
Metoprolol tartrate Injection, USP, is a selective beta1-adrenoreceptor blocking agent, available in 5 mL vials for intravenous administration. Each vial contains a sterile solution of...
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent. This...
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies in animals have been conducted to evaluate the carcinogenic...
14 CLINICAL STUDIES
In a large (1,395 patients randomized), double-blind, placebo-controlled clinical study, Metoprolol tartrate was shown to reduce 3-month mortality by 36% in patients with suspected or definite myocardial...
16 HOW SUPPLIED/STORAGE AND HANDLING
Metoprolol tartrate Injection, USP is available as:
17 PATIENT COUNSELING INFORMATION
Advise patients (1) to avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the patient's response to therapy with Metoprolol tartrate has been...
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this product, click the link below to submit your information: Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer product, please call Pfizer Medical Information at (800) 438-1985.
(800)-332-1088.